Angiex Featured as a North American Biotech Leader in Drug Discovery World
Angiex has been recognized in Drug Discovery World as one of North America's most innovative biotech companies, spotlighted for its pioneering work on nuclear-delivered antibody-drug conjugates (ND-ADCs) and TM4SF1-directed therapies targeting solid tumors. The article highlights Angiex’s recent milestone of dosing the first patient in its Phase I clinical trial for AGX101, a first-in-class ADC targeting tumor blood vessels.
In the feature, Angiex’s CEO and Founder, Paul Jaminet, emphasized how Cambridge’s biotech infrastructure was instrumental in the company’s launch. “For entrepreneurs, the advantage of having ready access to expertise, capital, and a company incubation ecosystem is hard to overstate," Jaminet noted. "In our early years, we had limited funding and had to be very capital efficient, and having the resources of an incubator and the ability to share lab space was immensely helpful.” The support of LabCentral, located near MIT, played a pivotal role in Angiex’s early development, allowing the company to innovate and grow efficiently.
Drug Discovery World continues to highlight key biotech players driving innovation, and Angiex’s focus on groundbreaking cancer therapies underscores its leadership in advancing the future of oncology.